1158 / 1816
HER2 + patients
Weekly paclitaxel with anti-HER2 therapy is as effective as standard
chemotherapy for small cancers.
Available data shows, that only a fraction of patients benefit from any
particular instance of therapeutic escalation.
Evidence suggests that some patients with HER2-positive cancers may
be curable with anti-HER2 antibody therapy alone, and the
challenge is to identify these.
At this moment 1 year trastuzumab adjuvant will be daily practice
19-9-2017